Enhanced External Counterpulsation
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Enhanced external counterpulsation (EECP) is a noninvasive circulatory assist device that has been as a treatment option for refractory angina in left ventricular (LV) dysfunction. Recently, its potential role in heart failure management has been shown. However, although the concept of EECP was introduced almost four decades ago, and despite growing evidence supporting the clinical benefit and safety of this therapeutic modality, little is firmly established regarding the mechanisms responsible for the benefit of EECP include improvement in endothelial function, promotion of coronary collateralization, enhancement of ventricular function, and peripheral effects. Therefore, the major aim of this study is to provide an alternative treatment, EECP, for those unsuitable for standard procedures, especially for patients whose heart failure was caused by repeated myocardial infarction, called ischemic cardiomyopathy (ICMP), and to evaluate the clinical outcome and the endothelial function before and after 35 hours of EECP treatment.
| Condition |
|---|
|
Coronary Artery Disease Congestive Heart Failure |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Prospective |
| Official Title: | Enhanced External Counterpulsation for Ischemic Cardiomyopathy |
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Patients with ischemia coronary artery diseases and congestive heart failure not amenable to standard procedures
Inclusion Criteria:
- The inclusion criteria is left ventricular ejection fraction (LVEF) less than 40% by means of left ventricular angiography and symptomatic mild-to-moderate heart failure (New York Heart Association [NYHA] functional class II-III). The patient was included if there is no suitable target for either percutaneous coronary intervention or surgical bypass grafting.
Exclusion Criteria:
- IF he/she has moderate or severe aortic regurgitation (AR), history of deep vein thrombosis, or significant arrhythmia.
Contacts and Locations
More Information
No publications provided
| Responsible Party: | Shih-Hong Huang, Far Eastern Memorial Hospital |
| ClinicalTrials.gov Identifier: | NCT01355315 History of Changes |
| Other Study ID Numbers: | 95005, FEMH-95-C-039 |
| Study First Received: | June 18, 2008 |
| Last Updated: | May 17, 2011 |
| Health Authority: | Taiwan: Department of Health |
Keywords provided by Far Eastern Memorial Hospital:
|
EECP ischemic cardiomyopathy endothelin-1 ischemia coronary artery diseases congestive heart failure not amenable to standard procedures |
Additional relevant MeSH terms:
|
Coronary Artery Disease Myocardial Ischemia Coronary Disease Heart Failure Cardiomyopathies |
Heart Diseases Cardiovascular Diseases Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases |
ClinicalTrials.gov processed this record on May 16, 2013